跳至主要内容
临床试验/NCT00139971
NCT00139971Unknown3 期

Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer

West Japan Thoracic Oncology Group2 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2001年12月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
发起方
入组人数
600
试验地点
2
主要终点
5 year survival rate

研究概览

简要总结

To estimate the efficacy of Gemcitabine monotherapy compared to UFT as the post operative adjuvant chemotherapy for completely resected non-small cell lung cancer.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • completely resected non small cell lung cancer
  • no prior anti cancer treatment for thoracic malignancy exept for this operation
  • pathological stage IB, II, and stage IIIA with only one station of n2 disease
  • adequate organ function for chemotherapy
  • written informed consent

排除标准

  • small cell lung cancer or low grade malignancy of lung cancer
  • incomplete resection
  • apparent interstitial pneumonitis at chest rentogenogram
  • inadequate condition for chemotherapy

结局指标

主要结局

5 year survival rate

次要结局

  • Disease free survival

研究者

发起方
West Japan Thoracic Oncology Group
申办方类型
Other

研究点 (2)

Loading locations...

相似试验